OTCMKTS:ROSGQ

Rosetta Genomics Stock Forecast, Price & News

$0.09
+0.02 (+33.33 %)
(As of 04/13/2021 02:23 PM ET)
Add
Compare
Today's Range
$0.09
Now: $0.09
$0.11
50-Day Range
$0.07
MA: $0.10
$0.15
52-Week Range
$0.00
Now: $0.09
$0.39
Volume12,210 shs
Average Volume78,627 shs
Market Capitalization$164,700.00
P/E RatioN/A
Dividend YieldN/A
Beta6.39
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ROSGQ
CUSIPN/A
CIKN/A
Phone972 73 222 0700
Employees86
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$164,700.00
Next Earnings DateN/A
OptionableNot Optionable

Headlines

News for Rosetta Genomics Ltd.
December 30, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1849th out of 2,019 stocks

Pharmaceutical Preparations Industry

737th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.09
+0.02 (+33.33 %)
(As of 04/13/2021 02:23 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ROSGQ News and Ratings via Email

Sign-up to receive the latest news and ratings for ROSGQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rosetta Genomics (OTCMKTS:ROSGQ) Frequently Asked Questions

What stocks does MarketBeat like better than Rosetta Genomics?

Wall Street analysts have given Rosetta Genomics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rosetta Genomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Rosetta Genomics?

Rosetta Genomics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 1,200 shares, a decrease of 90.2% from the February 28th total of 12,300 shares. Based on an average trading volume of 38,900 shares, the short-interest ratio is currently 0.0 days.
View Rosetta Genomics' Short Interest
.

Who are Rosetta Genomics' key executives?

Rosetta Genomics' management team includes the following people:
  • Dr. Eti Meiri Ph.D., VP of Research (Age 53, Pay $125.48k)
  • Mr. Douglas Sites, Exec. VP of Sales & Marketing
  • Prof. Zvi Bentwich M.D., Deputy Chairman of the Scientific Advisory Board
  • Dr. Ayelet Hajt Ph.D., Head of Molecular Biology and Exec. VP of R&D (Age 58)
  • Mr. Mark R. Willig, Chief Commercial Officer (Age 62)

Who are some of Rosetta Genomics' key competitors?

What is Rosetta Genomics' stock symbol?

Rosetta Genomics trades on the OTCMKTS under the ticker symbol "ROSGQ."

How do I buy shares of Rosetta Genomics?

Shares of ROSGQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rosetta Genomics' stock price today?

One share of ROSGQ stock can currently be purchased for approximately $0.09.

How much money does Rosetta Genomics make?

Rosetta Genomics has a market capitalization of $164,700.00.

How many employees does Rosetta Genomics have?

Rosetta Genomics employs 86 workers across the globe.

What is Rosetta Genomics' official website?

The official website for Rosetta Genomics is www.rosettagenomics.com.

Where are Rosetta Genomics' headquarters?

Rosetta Genomics is headquartered at 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706.

How can I contact Rosetta Genomics?

Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The company can be reached via phone at 972 73 222 0700 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.